Mechanisms of bone metastasis

Cancer

Volumn 80, Issue 8 SUPPL., 1997, Pages 1546-1556

  Mundy, Gregory R ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Bone metastasis; Hypercalcemia; Osteoblastic metastases; Osteolysis; PTH rP

Indexed keywords

CYTOKINE; FIBROBLAST GROWTH FACTOR; GROWTH FACTOR; INTEGRIN; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; PARATHYROID HORMONE RELATED PROTEIN; PLATELET DERIVED GROWTH FACTOR; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; UVOMORULIN;

ANIMAL MODEL; BONE METASTASIS; BONE PAIN; BONE REMODELING; BREAST CANCER; CONFERENCE PAPER; HUMAN; HYPERCALCEMIA; NERVE COMPRESSION; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PATHOLOGIC FRACTURE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 0030879065     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19971015)80:8+<1546::aid-cncr4>3.0.co;2-i     Document Type: Conference Paper

References (99)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin 1996; 46:5-27.
2. Walther HE. Krebsmetastasen. Bens schwabe verlag. Switzerland: Basel, 1948.
3. Mundy GR, Bertolini DR. Bone destruction and hypercalcemia in plasma cell myeloma. Semin Oncol 1986; 13:291-9.
4. Galasko CSB. Skeletal metastases. Clin Orthop 1986;September: 18-30.
5. Galasko CSB. Skeletal metastases. London: Butterworth, 1986:1-160.
6. Batson OV. The function of the vertebral veins and their role in the spread of metastases. Ann Surg 1940; 112:138-49.
7. Coman DR, DeLong RP. The role of the vertebral venous system in the metastasis of cancer to the spinal column: experiments with tumour cell suspension in rats and rabbits. Cancer 1951; 4:610-8.
8. van den Brenk HAS, Burch WM, Kelley H, Orton C. Venous diversion trapping and growth of blood-borne cancer cells en route to the lungs. Br J Cancer 1975; 31:46-61.
9. Dodds PR, Caride VJ, Lytton B. The role of vertebral veins in the dissemination of prostatic carcinoma. J Urol 1981; 126:753.
10. Galasko CSB, Burn JI. Hypercalcemia in patients with advanced mammary cancer. Br Med J 1971; 3:573-7.
11. Mundy GR. Calcium homeostasis: hypercalcemia and hypocalcemia. United Kingdom: Martin Dunitz, 1990: 1-272.
12. Stewart AF, Horst R, Deftos LJ, Cadman EC, Lang R, Broadus AE. Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and nonhumoral groups. N Engl J Med 1980;303:1377-83.
13. Tuttle KR, Kunau RT, Loveridge N, Mundy GR. Altered renal calcium handling in hypercalcemia of malignancy. J Am Soc Nephrol 1991; 2:191-9.
14. Peacock M, Robertson WG, Nordin BEC. Relation between serum and urine calcium with particular reference to parathyroid activity. Lancet 1969; 1:384-6.
15. Percival RC, Yates AJP, Gray RES, Galloway J, Rogers K, Neal FE, et al. Mechanisms of malignant hypercalcemia in carcinoma of the breast. Br Med J 1985;291:776-9.
16. Gallacher SJ, Fraser WD, Patel U, Logue FC, Soukop M, Boyle IT, et al. Breast cancer-associated hypercalcaemia: a reassessment of renal calcium and phosphate handling. Ann Clin Biochem 1990;27:551-6.
17. Harinck HI, Bijvoet OL, Plantingh AS, Body JJ, Elte JW, Sleeboom HP, et al. Role of bone and kidney in tumor-induced hypercalcemia and its treatment with bisphosphonate and sodium chloride. Am J Med 1987;82:1133-42.
18. Liotta LA, Kohn E. Cancer invasion and metastases. JAMA 1990; 263:1123-6.
19. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889; 1:571-3.
20. Zetter BR. The cellular basis of site-specific tumor metastasis. N Engl J Med 1990;322:605-12.
21. Weiss L, Orr FW, Honn KV. Interactions between cancer cells and the microvasculature: a rate-regulator for metastasis. Clin Exp Metastasis 1989; 7:127-67.
22. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980; 284:67-8.
23. Liotta LA, Mandler R, Murano G, Katz DA, Gordon RK, Chiang PK, et al. Tumor cell autocrine motility factor. Proc Natl Acad Sci USA 1986; 83:3302-6.
24. Liotta LA, Steeg PS. Clues to the function of Nm23 and Awd proteins in development, signal transduction, and tumor metastasis provided by studies of dictyostelium discoideum. J Natl Cancer Inst 1990; 82:1170-2.
25. Albelda SM, Buck CA. Integrins and other cell adhesion molecules. FASEB J 1990; 4:2868-80.
26. Oka H, Shiozaki H, Kobayashi K, Inoue M, Tahara H, Kobayashi T, et al. Expression of E-cadherin cells adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res 1993; 53:1696-701.
27. Hashimoto M, Niwa O, Nitta Y, Takeichi M, Yokoro K. Unstable expression of E-cadherin adhesion molecules in metastatic ovarian tumor cells. Jpn J Cancer Res 1989; 80:459-63.
28. Mareel MM, Behrens J, Birchmeier W, DeBruyne GK, Vleminckx K, Hoogewijs A. Down-regulation of E-cadherin expression in Madin-Darby canine kidney (MDCK) cells inside tumors of nude mice. Int J Cancer 1991; 47:922-8.
29. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992;69:11-25.
30. 3 to adhere to lymph node vitronectin. J Clin Invest 1992; 90:1406-13.
31. 3 integrin in human melanoma cell invasion. Proc Natl Acad Sci USA 1992; 89:1557-61.
32. Nakai M, Mundy GR, Williams PJ, Boyce B, Yoneda T. A synthetic antagonist to laminin inhibits the formation of osteolytic metastases by human melanoma cells in nude mice. Cancer Res 1992; 52:5395-9.
33. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 1991; 251:1451-5.
34. Behrens J, Mareel MM, Van Roy FM, Birchmeier W. Dissecting tumor cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion. J Cell Biol 1989; 108:2435-47.
35. Vleminckx K, Vakaet L, Mareel M, Fliers W, Van Roy F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 1991; 66:107-19.
36. Sommers CL, Thompson EW, Torri JA, Kemler R, Gelmann EP, Byers SW. Cell adhesion molecule uvomorulin expression in human breast cancer cell lines: relationship to morphology and invasive capacities. Cell Growth Differ 1991; 2:365-72.
37. Mbalaviele G, Dunstan CR, Sasaki A, Williams PJ, Mundy GR, Yoneda T. E-cadherin expression in human breast cancer cells suppress the development of osteolytic bone metastases in experimental metastasis model. Cancer Res 1996; 56:4063-70.
38. Carr I, Orr FW. Current reviews: invasion and metastasis. Can Med Assoc J 1983; 128:1164-7.
39. Heppner G. Tumor heterogeneity. Cancer Res 1984; 214:2259-65.
40. Poste G. Pathogenesis of metastatic disease: implications for current therapy and for the development of new therapeutic strategies. Cancer Treat Rep 1986; 70:183-99.
41. Fidler IJ, Poste G. The cellular heterogeneity of malignant neoplasms: implications for adjuvant chemotherapy. Semin Oncol 1985; 12:207-21.
42. Fidler IJ. Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res 1978; 38:2651-60.
43. Nowell PC. The clonal evolution of tumor cell subpopulations. Science 1976; 194:23-8.
44. Miller FR. Tumor subpopulation interactions in metastasis. Invasion Metastasis 1983; 3:234-42.
45. Reedy AL, Fialkow PJ. Multicellular origin of fibrosarcomas in mice induced by the chemical carcinogen 3-methylcholanthrene. J Exp Med 1980; 150:878-87.
46. Garbisa S, Pozzatti R, Muschel RJ, Safflotti U, Ballin M, Goldfarb RH, et al. Secretion of type IV collagenolytic protease and metastatic phenotype: induction by transfection with c-Ha-ras but not c-Ha-ras plus AD2-Ela. Cancer Res 1987;47:1523-8.
47. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
48. Steeg PS, Bevilacqua G, Kopper L, Thoregeirsson VP, Talmadge JE, Liotta LA, et al. Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst 1988;80:200-4.
49. Ali IU, Lidereau R, Theillet C, Callahan R. Reduction to homozygosity of genes on chromosome 11 in human breast neoplasia. Science 1987;238:185-8.
50. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal tumor development. N Engl J Med 1988;319:525-32.
51. Baker SJ, Fearon ER, Nigro IM, Hamilton SR, Preisinger AC, Jesup JM, et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989;244:217-21.
52. Warren BA, Vales O. The adhesion of thromboplastic tumor emboli to vessel walls in vivo. Br J Exp Pathol 1972;53:301-13.
53. Winterbauer RH, Elfenbein IB, Ball WC. Incidence and clinical significance of tumor embolization to the lungs. Am J Med 1968; 45:271-90.
54. Hilgard P, Gordon-Smith EL. Microangiopathic hemolytic anemia and experimental tumor-cell emboli. Br J Haematol 1974; 26:651-9.
55. Basset P, Bellocq JP, Wolf C, Stoll I, Hutin P, Limacher JM, et al. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 1990; 348:699-704.
56. Mundy GR, DeMartino S, Rowe DW. Collagen and collagen-derived fragments are chemotactic for tumor cells. J Clin Invest 1981;68:1102-5.
57. Mundy GR, Poser JW. Chemotactic activity of the gamma-carboxyglutamic acid containing protein in bone. Calcif Tissue Int 1983;35:164-8.
58. Orr W, Varani J, Gondek MD, Ward PA, Mundy GR. Chemotactic responses of tumor cells to products of resorbing bone. Science 1979;203:176-9.
59. Orr FW, Varani J, Gondek MD, Ward PA, Mundy GR. Partial characterization of a bone derived chemotactic factor for tumor cells. Am J Pathol 1980;99:43-52.
60. Hauschka PV, Mavrakos AE, Iafrati MD, Doleman SE, Klagsbrun M. Growth factors in bone matrix: isolation of multiple types by affinity chromatography on heparin sepharose. J Biol Chem 1986;261:12665-74.
61. Boyde A, Maconnachie E, Reid SA, Delling G, Mundy GR. Scanning electron microscopy in bone pathology: review of methods. Potential and applications. Scanning Electron Microsc 1986;IV:1537-54.
62. Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R, et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 1995;55:3551-7.
63. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996;335:1785-91.
64. Eilon G, Mundy GR. Direct resorption of bone by human breast cancer cells in vitro. Nature 1978;276:726-8.
65. Powell GJ, Southby J, Danks JA, Stillwell RG, Hayman JA, Henderson MA, et al. Localization of parathyroid hormone-related protein in breast cancer metastases - increased incidence in bone compared with other sites. Cancer Res 1991;51:3059-61.
66. Guise TA, Mundy GR. Physiological and pathological roles of parathyroid hormone-related protein. Curr Opin Nephrol 1996;5:307-15.
67. Guise TA, Yin JJ, Taylor SD, Yoneda T, Dallas M, Boyce BF, et al. Evidence for a casual role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 1996;98:1544-9.
68. Pfeilschifter J, Mundy GR. Modulation of transforming growth factor beta activity in bone cultures by osteotropic hormones. Proc Natl Acad Sci USA 1987;84:2024-8.
69. Yin JJ, Chirgwin JM, Taylor SD, Dallas J, Massague J, Mundy GR, et al. Dominant negative blockade of the transforming growth factor β (TGFβ) type II receptor decreases breast cancer-mediated osteolysis. J Bone Miner Res 1996; 11:(suppl 1)n:180.
70. DeLaMata J, Uy HL, Guise TA, Story B, Boyce BF, Mundy GR, et al. Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo. J Clin Invest 1995;95:2846-52.
71. Zakalik D, Diep D, Hooks MA, Nissenson RA, Strewler GJ. Transforming growth factor beta increases stability of parathyroid hormone related protein messenger RNA. J Bone Miner Res 1992; 7:(suppl 1)abstr:104.
72. Arguello F, Baggs RB, Frantz CN. A murine model of experimental metastasis to bone and bone marrow. Cancer Res 1988; 48:6876-81.
73. Yoneda T, Williams P, Dunstan C, Chavez J, Niewolna M, Mundy GR. Growth of metastatic cancer cells in bone is enhanced by bone derived insulin-like growth factors (IGFs). J Bone Miner Res 1995; 10:(suppl 1)abstr:P269.
74. Li X, Drucker DJ. Parathyroid hormone-related peptide is a downstream target for ras and src activation. J Biol Chem 1994; 269:6263-6.
75. Charhon SA, Chapuy MC, Delving EE, Valentin-Opran A, Edouard CM, Meunier PJ. Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma with special reference to osteomalacia. Cancer 1983;51:918-24.
76. Mundy GR. Pathophysiology of skeletal complications of cancer. Mundy GR, Martin TJ, editors. Physiology and pharmacology of bone. Handbook of experimental pharmacology. Berlin: Springer, 1993:641-71.
77. Pollard M, Luckert PH. Transplantable metastasizing prostate adenocarcinoma in rats. J Natl Cancer Inst 1975; 54:643-9.
78. Pollard M, Luckert PH, Scheu J. Effects of diphosphonate and x-rays on bone lesions induced in rats by prostate cancer cells. Cancer 1988; 61:2027-32.
79. Harris SE, Boyce B, Feng JQ, Mahy P, Harris M, Mundy GR. Antisense bone morphogenetic protein 3 (BMP 3) constructions decrease new bone formation in a prostate cancer model. J Bone Miner Res 1992; 7(suppl 1)abstr:92.
80. Achbarou A, Kaiser S, Tremblay G, Freeman MW, Kong X, Schipani E, et al. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res 1994; 54:2372-7.
81. Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, Finegold JJ, et al. Metastatic prostate cancer in a transgenic mouse. Cancer Res 1996; 56:4096-102.
82. Matuo Y, Nishi N, Matsui S, Sandberg AA, Isaacs JT, Wada F. Heparin binding affinity of rat prostate growth factor in normal and cancerous prostate: partial purification and characterization of rat prostate growth factor in the Dunning tumor. Cancer Res 1987; 47:188-92.
83. Mansson PE, Adams P, Kan M, McKeehan WL. HBGF1 gene expression in normal rat prostate and two transplantable rat prostate tumors. Cancer Res 1989; 49:2485-94.
84. Canalis E, Lorenzo J, Burgess WH, Maciag T. Effects of endothelial cell growth factor on bone remodeling in vitro. J Clin Invest 1987; 79:52-8.
85. Canalis E, Centrella M, McCarthy T. Effects of basic fibroblast growth factor on bone formation in vitro. J Clin Invest 1988; 81:1572-7.
86. Mayahara H, Ito T, Nagai H, Miyajima H, Tsukuda R, Taketomi S, et al. In vivo stimulation of endosteal bone formation by basic fibroblast growth factor in rats. Growth Factors 1993; 9:73-80.
87. Dunstan CR, Garrett IR, Adams R, Burgess W, Jaye M, Youngs T, et al. Systemic fibroblast growth factor (FGF-1) prevents bone loss, increases new bone formation, and restores trabecular microarchitecture in ovariectomized rats. J Bone Miner Res 1995; 10(suppl 1)abstr:P279.
88. Izbicka E, Dunstan C, Esparza J, Jacobs C, Sabatini M, Mundy GR. Human amniotic tumor which induces new bone formation in vivo produces a growth regulatory activity in vitro for osteoblasts identified as an extended form of basic fibroblast growth factor (bFGF). Cancer Res 1996; 56:633-6.
89. Rabbani SA, Desjardins J, Bell AW, Banville D, Mazar A, Henkin J, et al. An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells. Biochem Biophys Res Commun 1990a; 173:1058-64.
90. Rabbani SA, Desjardins J, Bell AW, Banville D, Goltzman D. Identification of a new osteoblast mitogen from a human prostate cancer cell line, PC-3. J Bone Miner Res 1990; 5:549.
91. Rabbani SA, Mazar AP, Bernier SM, Haq M, Bolivar T, Henkin J, et al. Structural requirements for the growth factor activity of the amino-terminal domain of urokinase. J Biol Chem 1992; 267:14151-6.
92. Dallas SL, Park-Snyder S, Miyazono K, Twardzik D, Mundy GR, Bonewald LF. Characterization and autoregulation of latent TGFβ complexes in osteoblast-like cell lines: production of a latent complex lacking the latent TGFβ-binding protein (LTBP). J Biol Chem 1994; 269:6815-22.
93. Dallas SL, Miyazono K, Skerry TM, Mundy GR, Bonewald LF. Dual role for the latent transforming growth factor-beta binding protein in storage of latent TGF-beta in the extracellular matrix and as a structural matrix protein. J Cell Biol 1995; 131:539-49.
94. Harris SE, Bonewald LF, Harris MA, Sabatini M, Dallas S, Feng J, et al. Effects of transforming growth factor beta on bone nodule formation and expression of bone morphogenic protein 2, osteocalcin, osteopontin, alkaline phosphatase, and type 1 collagen mRNA in long-term cultures of fetal rat calvarial osteoblasts. J Bone Miner Res 1994; 9:855-63.
95. Cramer SD, Chen Z, Peehl DM. Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: inactivation of PTH-rP stimulated cAMP accumulation in mouse osteoblasts. J Urol 1996; 156:1-6.
96. Takuwa Y, Ohue Y, Takuwa N, Yamashita K. Endothelin-1 activates phopholipase C and mobilizes Ca2+ from extra-and intracellular pools in osteoblastic cells. Am J Physiol 1989; 257:E797-803.
97. Takuwa Y, Masaki T, Yamashita K. The effects of the endothelin family peptides on cultured osteoblastic cells from rat calvariae. Biochem Biophys Res Commun 1990;170:998-1005.
98. Langenstroer P, Tang R, Shapiro E, Divish B, Opgenorth T, Lepor H. Endothelin-1 in the human prostate: tissue levels, source of production and isometric tension studies. J Urol 1993;150:495-9.
99. Nelson JB, Hedican SP, George DJ, Reddi AH, Plantadosi S, Eisenberger MA, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995;1:944-9.